David Askmyr

David Askmyr

Auto-generated profile, based on publicly available information

David Askmyr

Department of ORL, Head & Neck Surgery, Skåne University Hospital

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2024 in Science
Verified
Journal Article
Closed access
EAErvin Ascic
Ervin Ascic
FÅFritiof Åkerström
Fritiof Åkerström
MNMalavika Sreekumar Nair
Malavika Sreekumar Nair
ARAndré Rosa
André Rosa
IKIlia Kurochkin
Ilia Kurochkin
CPCarlos-Filipe Pereira
Carlos-Filipe Pereira
Immunotherapy can lead to long-term survival for some cancer patients, yet generalized success has been hampered by insufficient antigen presentation and exclusion of immunogenic cells from the tumor microenvironment. Here, we developed an approach to reprogram tumor cells in vivo by adenoviral delivery of the transcription factors PU.1, IRF8, and BATF3, which enabled them to present antigens as type 1 conventional dendritic cells. Reprogrammed tumor cells remodeled their tumor microenvironment, recruited, and expanded polyclonal cytotoxic T cells; induced tumor regressions; and established long-term systemic immunity in multiple mouse melanoma models. In human tumor spheroids and xenografts, reprogramming to immunogenic dendritic-like cells progressed independently of immunosuppression, which usually limits immunotherapy. Our study paves the way for human clinical trials of in vivo immune cell reprogramming for cancer immunotherapy.

5 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
ASAastha Sobti
Aastha Sobti
CSChristina Sakellariou
Christina Sakellariou
JNJohan S Nilsson
Johan S Nilsson
DADavid Askmyr
David Askmyr
LGLennart Greiff
Lennart Greiff
MLMalin Lindstedt
Malin Lindstedt
Nasopharyngeal cancer (NPC) is a malignant tumor. In a recent publication, we described the presence and distribution of CD8+ T cells in NPC and used the information to identify ‘inflamed’, ‘immune-excluded’, and ‘desert’ immune phenotypes, where ‘inflamed’ and ‘immune-excluded’ NPCs were correlated with CD8 T cell infiltration and survival. Arguably, more detailed and, in particular, spatially resolved data are required for patient stratification and for the identification of new treatment targets. In this study, we investigate the phenotype of CD45+ leukocytes in the previously analyzed NPC samples by applying multiplexed tissue analysis to assess the spatial distribution of cell types and to quantify selected biomarkers. A total of 47 specified regions-of-interest (ROIs) were generated based on CD45, CD8, and PanCK morphological staining. Using the GeoMx® Digital Spatial Profiler (DSP), 49 target proteins were digitally quantified from the selected ROIs of a tissue microarray consisting of 30 unique NPC biopsies. Protein targets associated with B cells (CD20), NK cells (CD56), macrophages (CD68), and regulatory T cells (PD-1, FOXP3) were most differentially expressed in CD45+ segments within ‘immune-rich cancer cell islet’ regions of the tumor (cf. ‘surrounding stromal leukocyte’ regions). In contrast, markers associated with suppressive populations of myeloid cells (CD163, B7-H3, VISTA) and T cells (CD4, LAG3, Tim-3) were expressed at a higher level in CD45+ segments in the ‘surrounding stromal leukocyte’ regions (cf. ‘immune-rich cancer cell islet’ regions). When comparing the three phenotypes, the ‘inflamed’ profile (cf. ‘immune-excluded’ and ‘desert’) exhibited higher expression of markers associated with B cells, NK cells, macrophages, and myeloid cells. Myeloid markers were highly expressed in the ‘immune-excluded’ phenotype. Granulocyte markers and immune-regulatory markers were higher in the ‘desert‘ profile (cf. ‘inflamed’ and ‘immune-excluded’). In conclusion, this study describes the spatial heterogeneity of the immune microenvironment in NPC and highlights immune-related biomarkers in immune phenotypes, which may aid in the stratification of patients for therapeutic purposes.

25 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
DJDavid Gomez Jimenez
David Gomez Jimenez
ASAastha Sobti
Aastha Sobti
DADavid Askmyr
David Askmyr
CSChristina Sakellariou
Christina Sakellariou
SSSofia Carreira Santos
Sofia Carreira Santos
MLMalin Lindstedt
Malin Lindstedt
Human papillomavirus (HPV) is the main causal agent of tonsillar cancer (TC) and HPV+ TC has a favorable prognosis compared to HPV− disease. In this study, we examined aspects of the tumor microenvironment of TC, focusing on T-cells, dendritic cells (DC), and macrophages. Fresh biopsies of TC and the contralateral healthy tonsil (HT) were obtained from 20 patients, analyzed by multiparameter flow cytometry, and assessed against a detailed HPV-status. Additionally, RNA-sequencing data from 38 TC samples available in the public database, The Cancer Genome Atlas (TCGA), were explored, focusing on the same leukocyte populations. HPV+ TC featured increased levels of CD8+ T-cells and antigen-presenting cells (cf. HPV− TC and HT, respectively). In HPV+ TC, CD8+ T-cell frequencies correlated to DC levels independently of tumor stage, HPV 16 copy number, and E7 oncogene expression as well as frequencies of other leukocytes. Similarly, RNA sequencing data were explored by dividing the HPV+ TCs according to predefined CD8+ T-cell scores in silico. Higher levels of genes expressed by antigen-presenting cells and effector T-cells, such as immune checkpoints and cytokines, were detected in the CD8HIGH HPV+ TC samples (cf. CD8LOW HPV+ TC). In conclusion, CD8HIGH HPV+ TC displays a unique inflammatory profile associated with increased effector T-cell functions and the presence of antigen-presenting cells in the tumor microenvironment. Further studies are warranted to assess if this information can be used on an individual basis to aid in prognosis and treatment decisions.

1 December 2021 in Human Immunology
Verified
Journal Article
Open access
DADavid Askmyr
David Askmyr
MAMilad Abolhalaj
Milad Abolhalaj
DJDavid Gomez Jimenez
David Gomez Jimenez
LGLennart Greiff
Lennart Greiff
MLMalin Lindstedt
Malin Lindstedt
KLKristina Lundberg
Kristina Lundberg
Dendritic cells (DCs) with capacity of antigen cross-presentation are of key interest for immunotherapy against cancer as they can induce antigen-specific cytotoxic T lymphocyte (CTL) responses. This study describes frequencies of DC subtypes in human tonsils and lymph nodes, and phenotypic aspects that may be targeted by adjuvant measures. From human tonsils and neck lymph nodes, DCs were identified through flow cytometry, and subsets of plasmacytoid DCs (pDCs) and myeloid DCs (mDCs) were investigated. Maturity status was assessed and surface receptors with CTL-promoting potentials were studied. CD123+ pDCs as well as CD1c+, CD141+, and CD1c-CD141- mDCs were detected in tonsils and lymph nodes. Both sites featured a similar presence of DC subsets, with CD123+ pDC being dominant and CD141+ mDCs least frequent. Based on CD80/CD86 expression, all DC subtypes featured a low degree of maturation. Expression of pattern recognition receptors (PRRs) CD206, CD207, DC-SIGN, TLR2, and TLR4, as well as the chemokine receptor XCR1, indicated DC subset-specific receptor profiles. We conclude that tonsils and lymph nodes share common features in terms of DC subset frequency and maturation as well as PRR and XCR1 expression pattern. Our work suggests that both sites may be considered for vaccine deposition in DC-mediated immunotherapy.

31 October 2025 in Acta Oto-Laryngologica
Verified
Journal Article
Open access
SSSabine Swoboda
Sabine Swoboda
RVRobertas Vanagas
Robertas Vanagas
CACan Altunbulakli
Can Altunbulakli
DADavid Askmyr
David Askmyr
MLMalin Lindstedt
Malin Lindstedt
LGLennart Greiff
Lennart Greiff
Age-related immunosenescence, also known as 'inflammageing', may impact the elderly's ability to mount immune responses against cancers and compromise the effectiveness of immune checkpoint inhibition (ICI). In this context, data on tonsillar cancer (TC), a subset of head and neck squamous cell cancer (HNSCC), are lacking. To compare the presence/distribution and features of immune cells in TC, and of bulk RNA-seq in HNSCC, between the young and the elderly. TC tissue microarrays (TMAs) characterised by GeoMx digital spatial profiling were revisited and analysed, focusing on quantification and location of CD8+ and CD11c+ immune cells. De novo analyses of the TMAs targeted CD68+/CD163+ macrophages. Bulk RNA-seq and clinical data from patients with HNSCC were sourced from the Cancer Genome Atlas (TCGA). For all data, patients were stratified into age groups. Immune-cell characteristics in TC were similar across young and elderly individuals, although the elderly exhibited higher PD-1 levels. TCGA data revealed increased immune checkpoint molecules PD-L1 and LAG-3 in the elderly, alongside immunosuppression. In the elderly, key immune cells are present in TC, and immune checkpoint molecules are overexpressed. This may be relevant to the stratification of patients for ICI.

19 May 2026 in Radiotherapy and Oncology
Verified
Journal Article
Open access
AHAndré Haraldsson
André Haraldsson
DADavid Askmyr
David Askmyr
CACan Altunbulakli
Can Altunbulakli
MNMikael Nilsson
Mikael Nilsson
JPJean-Philippe Pignol
Jean-Philippe Pignol
MGMaria Gebre-Medhin
Maria Gebre-Medhin
CD8 + T-cell presence and distribution in oropharyngeal cancer (OPC) reflects specific immune phenotypes and are linked to prognosis. Image processing methods such as convolutional neural networks (CNN) may enhance treatment decisions. From standard computed tomography (CT) images, this study evaluates radiomics in combination with machine learning models and CNN for prediction of spatially resolved CD8 + T-cell immune profiles and survival outcomes. Pre-treatment CT images were analysed using and comparing radiomics and CNNs to predict stroma-to-cancer cell islet CD8 + T-cell infiltration ratios (SIR) and immune phenotypes as determined from spatially resolved tissue-array. Open data with genomic and image information were used for external validation. Further, we predicted survival outcomes stratified with our model in OPC patients recruited to the ARTSCAN III randomised clinical trial, which compared cetuximab with cisplatin concurrent with radiotherapy. Our CNN model achieved an area under the curve (AUC) of 0.75 (range 0.71-0.81) in predicting high versus low SIR, performing better than radiomics. When stratifying the ARTSCAN III patients according to the CNN-derived immune scores, patients with an inflamed phenotype had improved local control (HR 0.03, 95% CI 0-0.23, p < 0.0001), progression-free survival (PFS) (HR 0.36, 95%CI 0.18-0.71, p = 0.003), and overall survival (HR 0.35, 95%CI 0.14-0.85, p = 0.02) in univariable and multivariable analyses. When stratifying the ARTSCAN III patients by type of chemotherapy, high immune score classification corresponded to better PFS in cetuximab-treated patients. Our findings indicate the potential of CNNs to predict CD8 + T-cell infiltration in OPC, offering a promising non-invasive tool for treatment stratification and personalised therapy.